Why is the UK subscription model for antibiotics considered successful?

Rebecca E. Glover; Andrew Singer; Adam Roberts; Claas Kirchhelle

doi:10.1016/s2666-5247(23)00250-1

Why is the UK subscription model for antibiotics considered successful?

Rebecca E. Glover, Andrew Singer, Adam Roberts, Claas Kirchhelle

Tropical Disease Biology

Research output: Contribution to journal › Comment/debate

7 Citations (Scopus)

Abstract

Comment

Original language	English
Pages (from-to)	e852-e853
Journal	The Lancet Microbe
Volume	4
Issue number	11
DOIs	https://doi.org/10.1016/s2666-5247(23)00250-1
Publication status	Published - 22 Aug 2023

Access to Document

10.1016/s2666-5247(23)00250-1Licence: CC BY-NC-ND

PIIS2666524723002501Final published version, 55.4 KBLicence: CC BY-NC-ND

Cite this

@article{11ad3d4ac3944c6cb01702ca2dc59513,

title = "Why is the UK subscription model for antibiotics considered successful?",

abstract = "Comment",

author = "Glover, \{Rebecca E.\} and Andrew Singer and Adam Roberts and Claas Kirchhelle",

year = "2023",

month = aug,

day = "22",

doi = "10.1016/s2666-5247(23)00250-1",

language = "English",

volume = "4",

pages = "e852--e853",

journal = "The Lancet Microbe",

issn = "2666-5247",